Skip to main content
. 2023 Jun 7;11(6):e006802. doi: 10.1136/jitc-2023-006802

Table 1.

Patients’ characteristics

Factor Category Discovery Validation
N % N %
Age Median 67 64
IQR 21.5 22
Sex Female 34 37.0 18 36.7
Male 58 63.0 31 63.3
Center Tübingen 67 72.8 42 85.7
Dresden 17 18.5 7 14.3
Lübeck 8 8.7 0 0.0
Therapy Anti-PD-1 51 55.4 14 28.6
2 mg/kg once every 3 weeks Pembro 42 45.7 8 16.3
3 mg/kg once every 3 weeks Pembro 3 3.3 0 0.0
4 mg/kg once every 6 weeks Pembro 1 1.1 0 0.0
400 mg once every 6 weeks Pembro 0 0.0 1 2,0
3 mg/kg once every 2 weeks Nivo 5 5.4 0 0.0
240 mg once every 2 weeks Nivo 0 0.0 1 2.0
480 mg once every 4 weeks Nivo 0 0.0 4 8.2
Anti-PD-1+anti-CTLA-4 41 44.6 35 71.4
1 mg/kg Ipi+3 mg/kg Nivo once every 3 weeks 4 4.3 3 6.1
3 mg/kg Ipi+1 mg/kg Nivo once every 3 weeks 37 40.2 32 65.3
Previous systemic therapies Immunotherapy 20 21.7 15 30.6
Targeted therapy 22 23.9 10 20.4
Chemotherapy 4 4.3 4 8.2
None 56 60.9 26 53.1
LDH serum level BL Normal 42 45.7 20 40.8
Elevated 50 54.3 27 55.1
Unknown 0 0.0 2 4.1

BL, baseline; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; Ipi, ipilimumab; LDH, lactate dehydrogenase; n.a., not available; Nivo, nivolumab; PD-1, programmed cell death protein 1; Pembro, pembrolizumab.